Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Cash (2016 - 2025)

Altimmune (ALT) has disclosed Change in Cash for 16 consecutive years, with -$17.5 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 420.54% to -$17.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, up 106.96% year-over-year, with the annual reading at $6.8 million for FY2025, 106.96% up from the prior year.
  • Change in Cash for Q4 2025 was -$17.5 million at Altimmune, up from -$121.9 million in the prior quarter.
  • The five-year high for Change in Cash was $134.0 million in Q2 2025, with the low at -$121.9 million in Q3 2025.
  • Average Change in Cash over 5 years is -$3.6 million, with a median of -$7.4 million recorded in 2022.
  • The sharpest move saw Change in Cash skyrocketed 1370.9% in 2021, then crashed 1202.89% in 2022.
  • Over 5 years, Change in Cash stood at $15.4 million in 2021, then plummeted by 206.03% to -$16.4 million in 2022, then soared by 394.86% to $48.3 million in 2023, then crashed by 88.7% to $5.5 million in 2024, then plummeted by 420.54% to -$17.5 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$17.5 million, -$121.9 million, and $134.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.